Acute Myeloid Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
AML is a heterogeneous group of blood cancers that result from clonal expansion of myeloid hematopoietic precursors in the bone marrow.
This PDQ cancer information summary for health professionals provides comprehensive, peer‑reviewed, evidence‑based information about the treatment of acute myeloid leukemia (AML). It is intended as a resource to inform and assist clinicians in the care of their patients and is not a policy statement or formal guideline.
It explains the pathogenesis of AML and underpins diagnostic and therapeutic strategies.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Recent advances on blinatumomab for acute lymphoblastic leukemia
- NCT05800210: Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
- Advancing the Diagnosis of Non‑Hodgkin Lymphoma Through Next‑Generation Sequencing in Developing Countries: An Evaluation of Progress — A Narrative Review
- The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia
- Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®)